WO2019220420A1 - Timbre non aqueux aux caractéristiques d'adhérence supérieures - Google Patents

Timbre non aqueux aux caractéristiques d'adhérence supérieures Download PDF

Info

Publication number
WO2019220420A1
WO2019220420A1 PCT/IB2019/054155 IB2019054155W WO2019220420A1 WO 2019220420 A1 WO2019220420 A1 WO 2019220420A1 IB 2019054155 W IB2019054155 W IB 2019054155W WO 2019220420 A1 WO2019220420 A1 WO 2019220420A1
Authority
WO
WIPO (PCT)
Prior art keywords
adhesion
lidocaine
patient population
hours
patch
Prior art date
Application number
PCT/IB2019/054155
Other languages
English (en)
Inventor
William PEDRANTI
Emileigh GRUBER
Kip VOUGHT
Original Assignee
Pedranti William
Gruber Emileigh
Vought Kip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pedranti William, Gruber Emileigh, Vought Kip filed Critical Pedranti William
Publication of WO2019220420A1 publication Critical patent/WO2019220420A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

La présente invention concerne des adhésifs et des timbres non aqueux contenant de la lidocaïne, qui ont des caractéristiques d'adhérence supérieures, et des méthodes d'administration de ces adhésifs et timbres de sorte que les patients reçoivent une quantité efficace de lidocaine sans entraîner d'effets secondaires excessifs. La présente invention concerne également des méthodes d'administration d'un médicament à une population de patients, comprenant l'application à une population de patients d'un adhésif non-aqueux contenant le médicament, l'adhésif maintenant au moins 90% d'adhésion à au moins 90% de la population de patients pendant une période d'administration, l'adhésion étant déterminée par un test standard mais n'étant pas limité au classement d'adhésion FDA ou au classement d'adhésion EMA.
PCT/IB2019/054155 2018-05-18 2019-05-20 Timbre non aqueux aux caractéristiques d'adhérence supérieures WO2019220420A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862762753P 2018-05-18 2018-05-18
US62/762,753 2018-05-18

Publications (1)

Publication Number Publication Date
WO2019220420A1 true WO2019220420A1 (fr) 2019-11-21

Family

ID=68541158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/054155 WO2019220420A1 (fr) 2018-05-18 2019-05-20 Timbre non aqueux aux caractéristiques d'adhérence supérieures

Country Status (1)

Country Link
WO (1) WO2019220420A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765749B2 (en) 2011-05-10 2020-09-08 Itochu Chemical Frontier Corporation Non-aqueous patch
US10765640B2 (en) 2011-09-27 2020-09-08 Itochu Chemical Frontier Corporation Non-aqueous patch
US11278623B2 (en) 2011-05-10 2022-03-22 Itochu Chemical Frontier Corporation Non-aqueous patch
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017034031A1 (fr) * 2015-08-27 2017-03-02 国立研究開発法人国立精神・神経医療研究センター Procédé de diagnostic d'une maladie auto-immune, biomarqueur de diagnostic d'une maladie auto-immune, et agent de prévention ou de traitement d'une maladie auto-immune

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017034031A1 (fr) * 2015-08-27 2017-03-02 国立研究開発法人国立精神・神経医療研究センター Procédé de diagnostic d'une maladie auto-immune, biomarqueur de diagnostic d'une maladie auto-immune, et agent de prévention ou de traitement d'une maladie auto-immune

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAGHPANAH S ET AL: "Application Number: 207962Org1s000 Summary review", 28 February 2018 (2018-02-28), Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/nda2018/207962Orig1S000SumR.pdf> *
HOFFMAN M: "FDA Approves Lidocaine Patch 1.8% for Post-Herpetic Neuralgia", HCP LIVE, 28 February 2018 (2018-02-28), Retrieved from the Internet <URL:https://www.mdmag.com/medical-news/fda-approves-lidocaine-patch-18-for-postherpetic-nerualgia> *
SCHRIEVEN J: "Patch adhesion and local tolerability of", FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES, 16 March 2013 (2013-03-16), pages 1 - 20, XP055680293, Retrieved from the Internet <URL:https://www.agah.eu/wp-content/uploads/Schriever_patch_adhesion_local_tolerability.pdf> *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765749B2 (en) 2011-05-10 2020-09-08 Itochu Chemical Frontier Corporation Non-aqueous patch
US11278623B2 (en) 2011-05-10 2022-03-22 Itochu Chemical Frontier Corporation Non-aqueous patch
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
US10765640B2 (en) 2011-09-27 2020-09-08 Itochu Chemical Frontier Corporation Non-aqueous patch
US11793766B2 (en) 2011-09-27 2023-10-24 ITOCHU CHEMICAL FRONTIER Corporation; Non-aqueous patch for the relief of pain

Similar Documents

Publication Publication Date Title
WO2019220420A1 (fr) Timbre non aqueux aux caractéristiques d&#39;adhérence supérieures
JP5117196B2 (ja) 冷却局所用貼付製剤
CA2645823C (fr) Systeme therapeutique transdermique contenant de la norelgestromine pour la contraception et la substitution hormonale
CA1338779C (fr) Methode pour traiter les douleurs associees au zona et les nevralgies post-zona grace a l&#39;application topique d&#39;anesthesiques locaux
TWI242452B (en) A composition for topical application of methylphenidate and a pharmaceutical composition for treating attention deficit disorder and attention deficit/hyperactivity disorder
TWI629066B (zh) 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
JP2010500992A (ja) アルツハイマー病の経皮的治療法及び経皮的治療システム
ES2338860T3 (es) Sistema y procedimiento de administracion de anticonceptivos transdermica mejorado.
Ball et al. Optimizing transdermal drug therapy
US20200230073A1 (en) Non-aqueous patch comprising lidocaine
KR20090117839A (ko) 지연형 감각 과민성 유발 물질 함유 국소용 패치 제제 및 그의 사용 방법
Nalamachu et al. Characteristics of analgesic patch formulations
CN101541315A (zh) 抗真菌病用贴剂
Nakai et al. Fixed drug eruption caused by fluconazole: a case report and mini-review of the literature
Bershow et al. Cutaneous reactions to transdermal therapeutic systems
JP2001302501A (ja) 肩こり・膝関節痛・五十肩等の治療用貼付剤
Hughes et al. Appropriate use of transdermal drug delivery systems
EP3818982B1 (fr) Système thérapeutique à base de tizanidine
TW202228688A (zh) 用於神經退化性疾病之症狀緩解或治療之貼附劑
CA2803339A1 (fr) Polytherapie par cryochirurgie et imiquimod a faible intensite de dosage pour traiter la keratose senile
JPH111428A (ja) 温感パップシート
KR101449527B1 (ko) 희토류 원소를 포함하는 패치 제품
JPH07277961A (ja) 経皮吸収製剤
WO2018063876A1 (fr) Systèmes d&#39;administration transdermique et/ou topique comprenant du dichlorhydrate de cétirizine
WO2021037199A1 (fr) Composition pharmaceutique transdermique contenant un anesthesique local de type amide et procédé de préparation associé

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19804347

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19804347

Country of ref document: EP

Kind code of ref document: A1